Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.

Dan, Jennifer M., Mateus, Jose, Kato, Yu, Hastie, Kathryn M., Yu, Esther Dawen, Faliti, Caterina E., Grifoni, Alba, Ramirez, Sydney I. +13 more·2021·Science
DOI 10.1126/science.abf4063

Cited by (1,011)

Items 101–200 of 1,011

  1. Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset
    S. Anand, Jérémie Prévost, M. Nayrac, G. Beaudoin-Bussières, M. Benlarbi, Romain Gasser, N. Brassard, A. Laumaea, S. Gong, C. Bourassa et al. · 2021 · bioRxiv
  2. Prolonged evolution of the human B cell response to SARS-CoV-2 infection
    Sakharkar, Mrunal, Rappazzo, C. Garrett, Wieland-Alter, Wendy F., Hsieh, Ching-Lin, Wrapp, Daniel, Esterman, Emma S., Kaku, Chengzi I., Wec, Anna Z., Geoghegan, James C., McLellan, Jason S. et al. · 2021 · Science Immunology
  3. Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity
    D. Hagin, Tal Freund, M. Navon, T. Halperin, Dikla Adir, Rotem Marom, Inbar Levi, S. Benor, Y. Alcalay, N. Freund · 2021 · Journal of Allergy and Clinical Immunology
  4. Integrated longitudinal immunophenotypic, transcriptional, and repertoire analyses delineate immune responses in patients with COVID-19
    Samuele Notarbartolo, Valeria Ranzani, Alessandra Bandera, Paola Gruarin, Valeria Bevilacqua, Anna Rita Putignano, Andrea Gobbini, Eugenia Galeota, Cristina Manara, Mauro Bombaci et al. · 2021 · Science Immunology
  5. Immune signatures underlying post-acute COVID-19 lung sequelae
    In Su Cheon, Chaofan Li, Young Min Son, N. Goplen, Yue Wu, Tiffany J. Cassmann, Zheng Wang, Xiaoqin Wei, Jinyi Tang, Yichen Li et al. · 2021 · Science Immunology
  6. Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword
    Li Yin Tan, Thamil Vaani Komarasamy, Vinod R. M. T. Balasubramaniam · 2021 · Frontiers in Immunology
  7. SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8 <sup>+</sup> T cell responses
    Agerer, Benedikt, Koblischke, Maximilian, Gudipati, Venugopal, Montaño-Gutierrez, Luis Fernando, Smyth, Mark, Popa, Alexandra, Genger, Jakob-Wendelin, Endler, Lukas, Florian, David M., Mühlgrabner, Vanessa et al. · 2021 · Science Immunology
  8. Defining the risk of SARS-CoV-2 variants on immune protection
    Marciela M. DeGrace, Elodie Ghedin, Matthew B. Frieman, Florian Krammer, Alba Grifoni, Arghavan Alisoltani, Galit Alter, Rama Rao Amara, Ralph Steven Baric, Dan H. Barouch et al. · 2022 · Nature
  9. Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses
    Natalia Ortega, Marta Ribes, Marta Vidal, Rocío Rubio, Ruth Aguilar, Sarah V Williams, Diana Barrios, Selena Alonso, Pablo Hernández-Luis, Robert A. Mitchell et al. · 2021 · Nature Communications
  10. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study
    Li Guo, Geng Wang, Yeming Wang, Qiao Zhang, Lili Ren, Xiaoying Gu, Tingxuan Huang, Jingchuan Zhong, Ying Wang, Xinming Wang et al. · 2022 · The Lancet Microbe
  11. Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination
    Edara, Venkata Viswanadh, Hudson, William H., Xie, Xuping, Ahmed, Rafi, Suthar, Mehul S. · 2021 · JAMA
  12. COVID-19 in long-term care
    Eileen Rocard, Paola Sillitti, Ana Llena Nozal · 2021 · OECD health working papers
  13. A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses
    Alexandra Tauzin, Manon Nayrac, Mehdi Benlarbi, Shang Yu Gong, Romain Gasser, Guillaume Beaudoin-Bussières, Nathalie Brassard, Annemarie Laumaea, Dani Vézina, Jérémie Prévost et al. · 2021 · Cell Host & Microbe
  14. Immunity to SARS‐CoV‐2 induced by infection or vaccination
    Xaquín Castro Dopico, Sebastian Ols, Karin Loré, Gunilla B. Karlsson Hedestam · 2021 · Journal of Internal Medicine
  15. Comparison of the immunogenicity of <scp>BNT162b2</scp> and <scp>CoronaVac COVID</scp> ‐19 vaccines in Hong Kong
    Mok, Chris Ka Pun, Cohen, Carolyn A., Cheng, Samuel M. S., Chen, Chunke, Kwok, Kin‐On, Yiu, Karen, Chan, Tat‐On, Bull, Maireid, Ling, Kwun Cheung, Dai, Zixi et al. · 2022 · Respirology
  16. Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation
    Florence WJ Chioh, Siew‐Wai Fong, Barnaby Edward Young, Kan Xing Wu, Anthony Siau, Shuba Krishnan, Yi‐Hao Chan, Guillaume Carissimo, Louis LY Teo, Fei Gao et al. · 2021 · eLife
  17. Alterations in T and B cell function persist in convalescent COVID-19 patients
    Halima Ali Shuwa, Tovah N. Shaw, Sean Knight, Kelly Wemyss, Flora A. McClure, Laurence Pearmain, Ian E. Prise, Christopher P. Jagger, David J. Morgan, Saba Khan et al. · 2020 · Med
  18. SARS-CoV-2-specific T cells in infection and vaccination
    Bertoletti, Antonio, Le Bert, Nina, Qui, Martin, Tan, Anthony T. · 2021 · Cellular &amp; Molecular Immunology
  19. Neutralization, effector function and immune imprinting of Omicron variants
    Amin Addetia, Luca Piccoli, James Brett Case, Young‐Jun Park, Martina Beltramello, Barbara Guarino, Ha V. Dang, Guilherme Dias de Melo, Dora Pinto, Kaitlin R. Sprouse et al. · 2023 · Nature
  20. T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals
    Tatjana Bilich, Annika Nelde, Jonas S. Heitmann, Yacine Maringer, Malte Roerden, Jens Bauer, Jonas Rieth, Marcel Wacker, Andreas Peter, Sebastian Hörber et al. · 2021 · Science Translational Medicine
  21. Antibody titres decline 3-month post-vaccination with BNT162b2
    Julien Favresse, Jean‐Louis Bayart, François Mullier, Marc Elsen, Christine Eucher, Sandrine Van Eeckhoudt, Tatiana Roy, Grégoire Wieërs, Christine Laurent, Jean‐Michel Dogné et al. · 2021 · Emerging Microbes & Infections
  22. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects
    Sarah Wheeler, Galina V. Shurin, Mary Yost, Adam Anderson, Lisa Pinto, Alan H. Wells, Michael R. Shurin · 2021 · Microbiology Spectrum
  23. COVID-19 and cellular senescence
    Schmitt, Clemens A., Tchkonia, Tamar, Niedernhofer, Laura J., Robbins, Paul D., Kirkland, James L., Lee, Soyoung · 2023 · Nature Reviews Immunology
  24. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant
    C. Graham, J. Seow, I. Huettner, Hataf Khan, N. Kouphou, S. Acors, H. Winstone, S. Pickering, R. P. Galão, L. Dupont et al. · 2021 · Immunity
  25. Adaptive Immune Responses and Immunity to SARS-CoV-2
    Dragan Primorac, Kristijan Vrdoljak, Petar Brlek, Eduard Pavelić, Vilim Molnar, Vid Matišić, Ivana Erceg Ivkošić, Marijo Parčina · 2022 · Frontiers in Immunology
  26. Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets
    Dugan, Haley L., Stamper, Christopher T., Li, Lei, Changrob, Siriruk, Asby, Nicholas W., Halfmann, Peter J., Zheng, Nai-Ying, Huang, Min, Shaw, Dustin G., Cobb, Mari S. et al. · 2021 · Immunity
  27. Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies
    Carla Tortorella, Alessandra Aiello, Claudio Gasperini, Chiara Agrati, Concetta Castilletti, Serena Ruggieri, Silvia Meschi, Giulia Matusali, Francesca Colavita, Chiara Farroni et al. · 2021 · Neurology
  28. Protective immunity after recovery from SARS-CoV-2 infection
    Noah Kojima, Jeffrey D Klausner · 2021 · The Lancet Infectious Diseases
  29. Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs
    Weingarten-Gabbay, Shira, Klaeger, Susan, Sarkizova, Siranush, Pearlman, Leah R., Chen, Da-Yuan, Gallagher, Kathleen M.E., Bauer, Matthew R., Taylor, Hannah B., Dunn, W. Augustine, Tarr, Christina et al. · 2021 · Cell
  30. Antibody-mediated neutralization of SARS-CoV-2
    Henning Gruell, Kanika Vanshylla, Timm Weber, Christopher O. Barnes, Christoph Kreer, Florian Klein · 2022 · Immunity
  31. Artificial intelligence-assisted colorimetric lateral flow immunoassay for sensitive and quantitative detection of COVID-19 neutralizing antibody
    Haoyang Tong, Chaoyu Cao, Minli You, Shuang Han, Zhe Liu, Ying Xiao, Wanghong He, Chang Liu, Ping Peng, Zhenrui Xue et al. · 2022 · Biosensors and Bioelectronics
  32. Signature of long-lived memory CD8+ T cells in acute SARS-CoV-2 infection
    S. Adamo, J. Michler, Y. Zurbuchen, Carlo Cervia, Patrick Taeschler, M. E. Raeber, Simona Baghai Sain, J. Nilsson, A. Moor, O. Boyman · 2021 · Nature
  33. COVID‐19 vaccinations: The unknowns, challenges, and hopes
    Kawthar Mohamed, Piotr Rzymski, Md Shahidul Islam, Rangarirai Makuku, Ayesha Mushtaq, Amjad Khan, Mariya Ivanovska, Sara A. Makka, Fareeda Hashem, Leander Penaso Marquez et al. · 2021 · Journal of Medical Virology
  34. SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants
    F. Tea, Alberto Ospina Stella, A. Aggarwal, David Ross Darley, Deepti Pilli, D. Vitale, V. Merheb, Fiona X. Z. Lee, Philip H. Cunningham, G. Walker et al. · 2021 · PLoS Medicine
  35. Understanding T cell responses to COVID-19 is essential for informing public health strategies
    Santosha Adipudi Vardhana, Lance Baldo, William George Morice, E. John Wherry · 2022 · Science Immunology
  36. Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?
    Kent, Stephen J., Khoury, David S., Reynaldi, Arnold, Juno, Jennifer A., Wheatley, Adam K., Stadler, Eva, John Wherry, E., Triccas, James, Sasson, Sarah C., Cromer, Deborah et al. · 2022 · Nature Reviews Immunology
  37. Association of Simulated COVID-19 Vaccination and Nonpharmaceutical Interventions With Infections, Hospitalizations, and Mortality
    Mehul D. Patel, Erik Rosenstrom, Julie Simmons Ivy, María E. Mayorga, Pınar Keskinocak, Ross M. Boyce, Kristen Hassmiller Lich, Raymond Smith, Karl Johnson, Paul L. Delamater et al. · 2021 · JAMA Network Open
  38. Scientific rationale for developing potent RBD-based vaccines targeting COVID-19
    H. Kleanthous, J. Silverman, K. Makar, I. Yoon, Nicholas A. C. Jackson, D. Vaughn · 2021 · npj Vaccines
  39. First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19
    Mazzoni, Alessio, Di Lauria, Nicoletta, Maggi, Laura, Salvati, Lorenzo, Vanni, Anna, Capone, Manuela, Lamacchia, Giulia, Mantengoli, Elisabetta, Spinicci, Michele, Zammarchi, Lorenzo et al. · 2021 · Journal of Clinical Investigation
  40. How to interpret and use COVID-19 serology and immunology tests
    David S. Y. Ong, Paraskevi C. Fragkou, Valentijn A. Schweitzer, Roy F. Chemaly, Charalampos D. Moschopoulos, Chrysanthi L. Skevaki · 2021 · Clinical Microbiology and Infection
  41. Immune response to SARS-CoV-2 variants of concern in vaccinated individuals
    Matthias Becker, Alex Dulovic, Daniel Junker, Natalia Ruétalo, Philipp D. Kaiser, Yudi Tatiana Pinilla, Constanze Heinzel, Julia Häring, Bjoern Traenkle, Teresa R. Wagner et al. · 2021 · Nature Communications
  42. Neutralising antibodies predict protection from severe COVID-19
    Cromer, Deborah, Steain, Megan, Reynaldi, Arnold, Schlub, Timothy E, Sasson, Sarah C, Kent, Stephen J, Khoury, David S, Davenport, Miles Philip · 2022
  43. Antibody Responses in COVID-19: A Review
    Mateo Chvatal‐Medina, Yorjagis Andres Mendez Cortina, Pablo Javier Patiño Grajales, Paula A. Velilla, Marı́a Teresa Rugeles · 2021 · Frontiers in Immunology
  44. Anti-spike antibody response to natural SARS-CoV-2 infection in the general population
    Jia Wei, Philippa Clare Matthews, Nicole E Stoesser, Thomas Maddox, Luke Lorenzi, Ruth Studley, John I. Bell, John N Newton, Jeremy Farrar, Ian D. Diamond et al. · 2021 · Nature Communications
  45. Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial
    Dean A. Follmann, Holly Janes, Olive D. Buhule, Honghong Zhou, Bethany Girard, Kristen Marks, Karen L. Kotloff, Michaël Desjardins, Lawrence Corey, Kathleen Maletic Neuzil et al. · 2022 · Annals of Internal Medicine
  46. Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants
    Saya Moriyama, Yu Adachi, Takashi Sato, K. Tonouchi, Lin Sun, S. Fukushi, S. Yamada, H. Kinoshita, K. Nojima, T. Kanno et al. · 2021 · Immunity
  47. Antibody response after first and second-dose of ChAdOx1-nCOV (CovishieldTM®) and BBV-152 (CovaxinTM®) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study
    Awadhesh Kumar Singh, Sanjeev Phatak, Ritu Singh, Kingshuk Bhattacharjee, Nagendra Kumar Singh, Arvind Gupta, Arvind Kumar Sharma · 2021 · Vaccine
  48. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study
    Thiago Cerqueira Silva, Jason Randolph Andrews, Viviane Sampaio Boaventura, Otavio Ranzani, Vinicius de Araújo Oliveira, Enny S Paixão, Juracy Bertoldo, Tales Mota Machado, Matt D. T. Hitchings, Murilo Dorion et al. · 2022 · The Lancet Infectious Diseases
  49. Controlling the pandemic during the SARS-CoV-2 vaccination rollout
    João Viana, Christiaan Hendrik van Dorp, Ana Nunes, Manuel C. Gomes, Michiel van Boven, Mirjam Kretzschmar, Marc Veldhoen, Ganna Rozhnova · 2021 · Nature Communications
  50. Antibody and B cell responses to SARS-CoV-2 infection and vaccination
    K. Röltgen, S. Boyd · 2021 · Cell Host and Microbe
  51. A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease
    Melissa M. Higdon, Brian Wahl, Carli B. Jones, Joseph G. Rosen, Shaun Truelove, Anurima Baidya, Anjalika Nande, Parisa A ShamaeiZadeh, Karoline K Walter, Daniel R. Feikin et al. · 2022 · Open Forum Infectious Diseases
  52. Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses
    Hall, Victoria G., Ferreira, Victor H., Wood, Heidi, Ierullo, Matthew, Majchrzak-Kita, Beata, Manguiat, Kathy, Robinson, Alyssia, Kulasingam, Vathany, Humar, Atul, Kumar, Deepali · 2022 · Nature Immunology
  53. CD8 T cells contribute to vaccine protection against SARS-CoV-2 in macaques
    Liu, Jinyan, Yu, Jingyou, McMahan, Katherine, Jacob-Dolan, Catherine, He, Xuan, Giffin, Victoria, Wu, Cindy, Sciacca, Michaela, Powers, Olivia, Nampanya, Felix et al. · 2022 · Science Immunology
  54. Reinfection Rates Among Patients Who Previously Tested Positive for Coronavirus Disease 2019: A Retrospective Cohort Study
    Megan M. Sheehan, Anita J Reddy, Michael B. Rothberg · 2021 · Clinical Infectious Diseases
  55. CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity
    Thi H. O. Nguyen, Louise C. Rowntree, Jan Petersen, Brendon Yew Loong Chua, Luca Hensen, Łukasz Kedzierski, Carolien E. van de Sandt, Priyanka Chaurasia, Hyon‐Xhi Tan, Jennifer R. Habel et al. · 2021 · Immunity
  56. Transition to endemicity: Understanding COVID-19
    Rustom Antia, M. Elizabeth Halloran · 2021 · Immunity
  57. Nanovaccine: an emerging strategy
    Amrita Das, Nahid Ali · 2021 · Expert Review of Vaccines
  58. Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine
    Yihao Liu, Qin Zeng, Caiguanxi Deng, Mengyuan Li, Liubing Li, Dayue Liu, Ming Liu, Xinyuan Ruan, Jie Mei, Ruohui Mo et al. · 2022 · Cell Discovery
  59. Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-CoV-2-specific CD8+ T cell responses following COVID-19
    Anna H.E. Roukens, Cilia R. Pothast, Marion H. König, Wesley Huisman, Tim J. Dalebout, Tamar Tak, Shohreh Azimi, Yvonne C. M. Kruize, Renate S. Hagedoorn, Mihaela Zlei et al. · 2021 · Nature Immunology
  60. RETRACTED: Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?
    Manish K. Dhawan, AbdulRahman A. Saied, Saikat Mitra, Fahad Abdulrahman Alhumaydhi, Talha Bin Emran, Polrat Wilairatana · 2022 · Biomedicine & Pharmacotherapy · Retracted
  61. Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?
    Gregory Milne, Thomas Hames, Chris J. Scotton, Nick Gent, Alexander Johnsen, Roy Malcolm Anderson, Tom Ward · 2021 · The Lancet Respiratory Medicine
  62. A scalable serology solution for profiling humoral immune responses to SARS‐CoV‐2 infection and vaccination
    Karen Colwill, Yannick Galipeau, M. Stuible, C. Gervais, C. Arnold, B. Rathod, K. Abe, Jenny H. Wang, A. Pasculescu, Mariam Maltseva et al. · 2022 · Clinical & Translational Immunology
  63. Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine
    Gebre, Makda S., Rauch, Susanne, Roth, Nicole, Yu, Jingyou, Chandrashekar, Abishek, Mercado, Noe B., He, Xuan, Liu, Jinyan, McMahan, Katherine, Martinot, Amanda et al. · 2022 · Nature
  64. Count on us: T cells in SARS-CoV-2 infection and vaccination
    Katherine Kedzierska, Paul Glyndwr Thomas · 2022 · Cell Reports Medicine
  65. COVID-19 vaccines for patients with cancer: benefits likely outweigh risks
    Joyce K. Hwang, Tian Zhang, Andrew Zhuang Wang, Zihai Li · 2021 · Journal of Hematology & Oncology
  66. An intranasal vaccine durably protects against SARS-CoV-2 variants in mice
    Ahmed O. Hassan, Swathi Shrihari, Matthew J. Gorman, Baoling Ying, Dansu Yuan, Saravanan Raju, Rita E. Chen, Igor P. Dmitriev, Elena A. Kashentseva, Lucas J. Adams et al. · 2021 · Cell Reports
  67. Vaccine nationalism and the dynamics and control of SARS-CoV-2
    Caroline E. Wagner, Chadi M. Saad-Roy, Sinead E. Morris, Rachel E. Baker, Michael Joseph Mina, Jeremy Farrar, Edward Charles Holmes, Oliver G. Pybus, Andrea L. Graham, Ezekiel Emanuel et al. · 2021 · Science
  68. Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants
    Brock A. Kingstad-Bakke, Woojong Lee, S Chandrasekar, David J. Gasper, Cristhian Salas-Quinchucua, Thomas Cleven, Jeremy A. Sullivan, Adel M. Talaat, Jorge E. Osorio, M. Suresh · 2022 · Proceedings of the National Academy of Sciences
  69. How to detect and reduce potential sources of biases in studies of SARS-CoV-2 and COVID-19
    Emma K. Accorsi, Xueting Qiu, Éva Rumpler, Lee Kennedy‐Shaffer, Rebecca J. Kahn, Keya Joshi, Edward Goldstein, Mats Julius Stensrud, René Niehus, Müge Çevik et al. · 2021 · European Journal of Epidemiology
  70. Tissues, not blood, are where immune cells function
    Donna L. Färber · 2021 · Nature
  71. Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike
    P. Tong, Avneesh Gautam, I. Windsor, M. Travers, Yuezhou Chen, Nicholas Garcia, Noah B. Whiteman, Lindsay G. A. McKay, N. Storm, Lauren E. Malsick et al. · 2021 · Cell
  72. Post-COVID-19 Syndrome
    Janet D. Pierce, Qiuhua Shen, Samantha A. Cintron, John B. Hiebert · 2021 · Nursing Research
  73. Optimal, near-optimal, and robust epidemic control
    Dylan H. Morris, Fernando W. Rossine, Joshua B. Plotkin, Simon A. Levin · 2021 · Communications Physics
  74. Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge
    Rodney Glenn King, Aarón Silva-Sánchez, Jessica N. Peel, Davide Botta, Alexandria M. Dickson, Amelia K. Pinto, Selene Meza‐Perez, S. Rameeza Allie, Michael D. Schultz, Mingyong Liu et al. · 2021 · Vaccines
  75. A look into the future of the COVID-19 pandemic in Europe: an expert consultation [viewpoint].
    Emil N. Iftekhar, Viola Priesemann, Rudi Balling, Simon Bauer, Philippe Beutels, André Sergej Calero Valdez, Sarah Cuschieri, Thomas Czypionka, Uga Dumpis, Enrico Glaab et al. · 2021 · BORIS (University Library Bern)
  76. Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year after recovery
    Chengqian Feng, Jingrong Shi, Qinghong Fan, Yaping Wang, Huang Huang, Fengjuan Chen, Guofang Tang, Youxia Li, Pingchao Li, Jiao Jiao Li et al. · 2021 · Nature Communications
  77. T‐cell activation–induced marker assays in health and disease
    Chad Poloni, Cole Schonhofer, Sabine M. Ivison, Megan K. Levings, Theodore S. Steiner, Laura E. Cook · 2023 · Immunology and Cell Biology
  78. Clinical Evaluation of the Abbott Alinity SARS-CoV-2 Spike-Specific Quantitative IgG and IgM Assays among Infected, Recovered, and Vaccinated Groups
    Madhusudhanan Narasimhan, Lenin Mahimainathan, Ellen Araj, Andrew E. Clark, John Markantonis, Allen P. Green, Jing Xu, Jeffrey A. SoRelle, Charles Alexis, Kimberly Fankhauser et al. · 2021 · Journal of Clinical Microbiology
  79. Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans
    M. Alejandra Tortorici, Amin Addetia, Albert J. Seo, Jack T Brown, Kaiti Sprouse, Jenni Logue, Erica Clark, Nicholas Franko, Helen Y. Chu, David Veesler · 2024 · Immunity
  80. To mix or not to mix? A rapid systematic review of heterologous prime–boost covid-19 vaccination
    Nan‐Chang Chiu, Hsin Chi, Yu‐Kang Tu, Ya-Ning Huang, Yu‐Lin Tai, Shun-Long Weng, Lung Chang, Daniel Tsung‐Ning Huang, Fu-Yuan Huang, Chien‐Yu Lin · 2021 · Expert Review of Vaccines
  81. Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2–experienced individuals
    Marie I. Samanovic, Amber R. Cornelius, Sophie L. Gray-Gaillard, Joseph R. Allen, Trishala Karmacharya, Jimmy P. Wilson, Sara Hyman, Michael Tuen, Sergei B. Koralov, Mark J. Mulligan et al. · 2022 · Science Translational Medicine
  82. Disease diagnostics using machine learning of B cell and T cell receptor sequences
    Maxim Zaslavsky, Erin Craig, Jackson Michuda, Nidhi Sehgal, Nikhil Ram-Mohan, Ji-Yeun Lee, Khoa D. Nguyen, Ramona A. Hoh, Tho D. Pham, Katharina Röltgen et al. · 2025 · Science
  83. SARS-CoV-2-specific T cells associate with inflammation and reduced lung function in pulmonary post-acute sequalae of SARS-CoV-2
    Katherine M. Littlefield, Renée O. Watson, Jennifer M. Schneider, Charles Preston Neff, Eiko Yamada, Min Zhang, Thomas Campbell, Michael T. Falta, Sarah E. Jolley, Andrew P. Fontenot et al. · 2022 · PLoS Pathogens
  84. SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic
    Antonio Bertoletti, Nina Le Bert, Anthony Tanoto Tan · 2022 · Immunity
  85. Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: A mathematical modelling analysis
    2021
  86. A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges
    Md. Mijanur Rahman, Md. Habib Ullah Masum, Shah Wajed, Asma Talukder · 2022 · VirusDisease
  87. COVID-19 reinfections among naturally infected and vaccinated individuals
    Sezanur Rahman, Md Mahfuzur Rahman, Mojnu Miah, Mst. Noorjahan Begum, Monira Sarmin, Mustafa Mahfuz, Mohammad Enayet Hossain, Mohammed Ziaur Rahman, Mohammod Jobayer Chisti, Tahmeed Ahmed et al. · 2022 · Scientific Reports
  88. Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes
    Edwards Pradenas, Benjamin Trinité, Víctor Urrea, Sílvia Marfil, Carlos Ávila‐Nieto, Maria Luisa Rodrı́guez de la Concepción, Ferran Tarrés-Freixas, Silvia Pérez-Yanes, Carla Rovirosa, Erola Ainsua‐Enrich et al. · 2021 · Med
  89. Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity
    Catherine Riou, Roanne Keeton, Thandeka Moyo-Gwete, Tandile Hermanus, Prudence Kgagudi, Richard Baguma, Ziyaad Valley‐Omar, Mikhail Smith, Houriiyah Tegally, Deelan Doolabh et al. · 2022 · Science Translational Medicine
  90. Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals
    Anthony Tanoto Tan, Joey Ming Er Lim, Nina Le Bert, Kamini Kunasegaran, Adeline Chia, Martin Qui, Nicole Tan, Wan Ni Chia, Ruklanthi de Alwis, Ding Ying et al. · 2021 · Journal of Clinical Investigation
  91. SARS-CoV-2 Omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine
    Ryutaro Kotaki, Yu Adachi, Saya Moriyama, Taishi Onodera, Shuetsu Fukushi, Takaki Nagakura, Keisuke Tonouchi, Kazutaka Terahara, Lin Sun, Tomohiro Takano et al. · 2022 · Science Immunology
  92. Immunological memory diversity in the human upper airway
    Sydney I. Ramirez, Farhoud Faraji, L. Benjamin Hills, Paul G. Lopez, Benjamin Goodwin, Hannah D. Stacey, Henry J. Sutton, Kathryn M. Hastie, Erica Ollmann Saphire, Hyun Jik Kim et al. · 2024 · Nature
  93. Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study
    Marit J. van Gils, A. H. Ayesha Lavell, Karlijn van der Straten, Brent Appelman, Ilja Bontjer, Meliawati Poniman, Judith A. Burger, Melissa Oomen, Joey H. Bouhuijs, Lonneke A. van Vught et al. · 2022 · PLoS Medicine
  94. Immune mechanisms underlying COVID-19 pathology and post-acute sequelae of SARS-CoV-2 infection (PASC)
    Sindhu Mohandas, Prasanna Jagannathan, Timothy J. Henrich, Zaki A. Sherif, Christian Bime, Erin Burke Quinlan, Michael A. Portman, Maria Laura Gennaro, Jalees Rehman, RECOVER Mechanistic Pathways Task Force · 2023 · eLife
  95. High-affinity memory B cells induced by SARS-CoV-2 infection produce more plasmablasts and atypical memory B cells than those primed by mRNA vaccines
    Kathryn A. Pape, Thamotharampillai Dileepan, Amanda J. Kabage, Daria Kozysa, Rodolfo Batres, Clayton Evert, Michael Matson, Sharon Lopez, Peter D. Krueger, Carolyn T. Graiziger et al. · 2021 · Cell Reports
  96. Predicting the efficacy of variant-modified COVID-19 vaccine boosters
    David S. Khoury, Steffen S. Docken, Kanta Subbarao, Stephen John Kent, Miles P. Davenport, Deborah Cromer · 2023 · Nature Medicine
  97. Immune Memory Response After a Booster Injection of mRNA-1273 for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
    Chu, Laurence, Montefiori, David, Huang, Wenmei, Nestorova, Biliana, Chang, Ying, Carfi, Andrea, Edwards, Darin K., Oestreicher, Judy, Legault, Holly, Girard, Bethany et al. · 2021
  98. Innate and adaptive immune responses to SARS-CoV-2 in humans: relevance to acquired immunity and vaccine responses
    Stanley C. Jordan · 2021 · Clinical & Experimental Immunology
  99. Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern
    L. Dupont, L. Snell, C. Graham, J. Seow, B. Merrick, T. Lechmere, T. Maguire, Sadie R. Hallett, S. Pickering, T. Charalampous et al. · 2021 · Nature Microbiology
  100. Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults
    Mark A. Brockman, Francis M. Mwimanzi, Hope R. Lapointe, Yurou Sang, Olga Agafitei, Peter K. Cheung, Siobhan Ennis, Kurtis Ng, Simran Basra, Li Yi Lim et al. · 2021 · The Journal of Infectious Diseases